Comparative study of three angiotensin II type 1 receptor antagonists in preventing liver fibrosis in diabetic rats: Stereology, histopathology, and electron microscopy

Journal of Molecular Histology

Volumn 43, Issue 6, 2012, Pages 723-735

  Sipal, Sare ^a   Halici, Zekai ^a   Kiki, Ilhami ^a   Polat, Beyzagul ^a   Albayrak, Abdulmecit ^a   Albayrak, Fatih ^a   Karakus, Emre ^a   Aksak, Selina ^a   Ozturk, Berna ^a   Gundogdu, Cemal ^a  

^a ATATURK UNIVERSITY   (Turkey)

Author keywords

Diabetes; Electron microscopy; Hepatic fibrosis; Losartan; Olmesartan; Stereology; Valsartan

Indexed keywords

LOSARTAN POTASSIUM; OLMESARTAN; VALSARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; DRUG DERIVATIVE; IMIDAZOLE DERIVATIVE; LOSARTAN; TETRAZOLE DERIVATIVE; VALINE;

ALLOXAN DIABETES MELLITUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEGENERATION; CELL DENSITY; CELL NUCLEUS MEMBRANE; CELL SWELLING; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOPLASM; DIABETES MELLITUS; ELECTRON MICROSCOPY; HISTOPATHOLOGY; LIVER CELL; LIVER FIBROSIS; LIVER MITOCHONDRION; LIVER NECROSIS; LIVER PROTECTION; LYSOSOME; MALE; MITOCHONDRIAL MEMBRANE; NONHUMAN; PRIORITY JOURNAL; RAT; STEREOLOGY; ANIMAL; EXPERIMENTAL DIABETES MELLITUS; LIVER CIRRHOSIS;

RATTUS;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; IMIDAZOLES; LIVER CIRRHOSIS; LOSARTAN; MALE; MICROSCOPY, ELECTRON; RATS; TETRAZOLES; VALINE;

EID: 84877146448     PISSN: 15672379     EISSN: 15672387     Source Type: Journal    
DOI: 10.1007/s10735-012-9441-z     Document Type: Article

References (46)

1. Altunkaynak BZ, Unal D, Altunkaynak ME, Halici Z, Kalkan Y, Keles ON, Aksak S, Selli J, Unal B (2012) Effects of diabetes and ovariectomy on rat hippocampus (a biochemical and stereological study). Gynecol Endocrinol 28(3):228-233. doi: 10.3109/09513590.2011.593662
2. Baddeley AJ, Gundersen HJ, Cruz-Orive LM (1986) Estimation of surface area from vertical sections. J Microsc 142(Pt 3):259-276
3. Bataller R, Schwabe RF, Choi YH, Yang L, Paik YH, Lindquist J, Qian T, Schoonhoven R, Hagedorn CH, Lemasters JJ, Brenner DA (2003) NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J Clin Invest 112(9):1383-1394 (Pubitemid 38057692)
4. Bataller R, Gabele E, Parsons CJ, Morris T, Yang L, Schoonhoven R, Brenner DA, Rippe RA (2005) Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct-ligated rats. Hepatology 41(5):1046-1055. doi: 10.1002/hep.20665 (Pubitemid 40593912)
5. Brilla CG (2000) Renin-angiotensin-aldosterone system and myocardial fibrosis. Cardiovasc Res 47(1):1-3 (Pubitemid 30408542)
6. Carey RM, Siragy HM (2003) Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev 24(3):261-271 (Pubitemid 36733542)
7. de Oliveira CAM, Luciano E, Marcondes MCCG, de Mello MAR (2007) Effects of swimming training at the intensity equivalent to aerobic/anaerobic metabolic transition in alloxan diabetic rats. J Diabetes Complicat 21(4):258-264 (Pubitemid 47002318)
8. Dorph-Petersen KA, Pierri JN, Sun Z, Sampson AR, Lewis DA (2004) Stereological analysis of the mediodorsal thalamic nucleus in schizophrenia: volume, neuron number, and cell types. J Comp Neurol 472(4):449-462. doi: 10.1002/cne.20055 (Pubitemid 38508829)
9. Erbe DV, Gartrell K, Zhang YL, Suri V, Kirincich SJ, Will S, Perreault M, Wang S, Tobin JF (2006) Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists. Vascul Pharmacol 45(3):154-162. doi: 10.1016/j.vph.2006.05.002 (Pubitemid 44716729)
10. Garcia-Pagan JC, Bosch J, Rodes J (1995) The role of vasoactive mediators in portal hypertension. Semin Gastrointest Dis 6(3):140-147
11. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, Spertus JA, Costa F (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112(17):2735-2752 (Pubitemid 41532612)
12. Gundersen HJ, Jensen EB, Kieu K, Nielsen J (1999) The efficiency of systematic sampling in stereology-reconsidered. J Microsc 193(Pt 3):199-211 (Pubitemid 29145155)
13. Halici Z, Bilen H, Albayrak F, Uyanik A, Cetinkaya R, Suleyman H, Keles ON, Unal B (2009) Does telmisartan prevent hepatic fibrosis in rats with alloxan-induced diabetes? Eur J Pharmacol 614(1-3):146-152. doi: 10.1016/j.ejphar.2009.04.042
14. Hirose A, Ono M, Saibara T, Nozaki Y, Masuda K, Yoshioka A, Takahashi M, Akisawa N, Iwasaki S, Oben JA, Onishi S (2007) Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology 45(6):1375-1381. doi: 10.1002/hep.21638 (Pubitemid 46918321)
15. Howard CV, Reed MG (1998) Unbiased stereology. Three dimensional measurement in microscopy. Bios Scientific Publishers, Oxford
16. Jin H, Yamamoto N, Uchida K, Terai S, Sakaida I (2007) Telmisartan prevents hepatic fibrosis and enzyme-altered lesions in liver cirrhosis rat induced by a choline-deficient L-amino acid-defined diet. Biochem Biophys Res Commun 364(4):801-807. doi: 10.1016/j.bbrc.2007.10.083 (Pubitemid 350103697)
17. Kanno K, Tazuma S, Nishioka T, Hyogo H, Chayama K (2005) Angiotensin II participates in hepatic inflammation and fibrosis through MCP-1 expression. Digest Dis Sci 50(5):942-948 (Pubitemid 40684916)
18. Kaplan S, Canan S, Aslan H, Unal B, Sahin B (2001) A simple technique to measure the movements of the microscope stage along the x and y axes for stereological methods. J Microsc 203(Pt 3):321-325 (Pubitemid 33755971)
19. Kim MY, Baik SK, Park DH, Jang YO, Suk KT, Yea CJ, Lee IY, Kim JW, Kim HS, Kwon SO, Cho MY, Ko SB, Chang SJ, Um SH, Han KH (2008) Angiotensin receptor blockers are superior to angiotensin-converting enzyme inhibitors in the suppression of hepatic fibrosis in a bile duct-ligated rat model. J Gastroenterol 43(11):889-896. doi: 10.1007/s00535-008-2239-9
20. Kitamura K, Tada S, Nakamoto N, Toda K, Horikawa H, Kurita S, Tsunematsu S, Kumagai N, Ishii H, Saito H, Hibi T (2007) Rho/Rho kinase is a key enzyme system involved in the angiotensin II signaling pathway of liver fibrosis and steatosis. J Gastroenterol Hepatol 22(11):2022-2033. doi: 10.1111/j.1440-1746. 2006.04735.x (Pubitemid 47525076)
21. Klover PJ, Mooney RA (2004) Hepatocytes: critical for glucose homeostasis. Int J Biochem Cell Biol 36(5):753-758 (Pubitemid 38299389)
22. Kurikawa N, Suga M, Kuroda S, Yamada K, Ishikawa H (2003) An angiotensin II type 1 receptor antagonist, olmesartan medoxomil, improves experimental liver fibrosis by suppression of proliferation and collagen synthesis in activated hepatic stellate cells. Br J Pharmacol 139(6):1085-1094. doi: 10.1038/sj.bjp.0705339 (Pubitemid 36920670)
23. Lee MH, Song HK, Ko GJ, Kang YS, Han SY, Han KH, Kim HK, Han JY, Cha DR (2008) Angiotensin receptor blockers improve insulin resistance in type 2 diabetic rats by modulating adipose tissue. Kidney Int 74(7):890-900. doi: 10.1038/ki.2008.313
24. Liu Z (2007) The renin-angiotensin system and insulin resistance. Curr Diab Rep 7(1):34-42 (Pubitemid 46344187)
25. Mattfeldt T, Mall G, Gharehbaghi H, Moller P (1990) Estimation of surface area and length with the orientator. J Microsc 159(Pt 3):301-317 (Pubitemid 20313604)
26. Nabeshima Y, Tazuma S, Kanno K, Hyogo H, Chayama K (2009) Deletion of angiotensin II type I receptor reduces hepatic steatosis. J Hepatol 50(6):1226-1235. doi: 10.1016/j.jhep.2009.01.018
27. Nyengaard JR, Gundersen HJG (1992) The Isector - a Simple and Direct Method for Generating Isotropic, Uniform Random Sections from Small Specimens. J Microsc-Oxford 165:427-431
28. Paizis G, Gilbert RE, Cooper ME, Murthi P, Schembri JM, Wu LL, Rumble JR, Kelly DJ, Tikellis C, Cox A, Smallwood RA, Angus PW (2001) Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis. J Hepatol 35(3):376-385 (Pubitemid 32844192)
29. Rao BK, Kesavulu MM, Giri R, Appa Rao C (1999) Antidiabetic and hypolipidemic effects of Momordica cymbalaria Hook. fruit powder in alloxan-diabetic rats. J Ethnopharmacol 67(1):103-109 (Pubitemid 29389749)
30. Sanchez SS, Abregu AV, Aybar MJ, Sanchez Riera AN (2000) Changes in liver gangliosides in streptozotocin-induced diabetic rats. Cell Biol Int 24(12):897-904. doi: 10.1006/cbir.1999.0452 (Pubitemid 32057572)
31. Scheen AJ (2004) Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab 30(6):487-496 (Pubitemid 40070350)
32. Steckelings UM, Rompe F, Kaschina E, Unger T (2009) The evolving story of the RAAS in hypertension, diabetes and CV disease: moving from macrovascular to microvascular targets. Fundam Clin Pharmacol 23(6):693-703. doi: 10.1111/j.1472-8206.2009.00780.x
33. Sun Y, Zhang J, Zhang JQ, Ramires FJ (2000) Local angiotensin II and transforming growth factor-beta1 in renal fibrosis of rats. Hypertension 35(5):1078-1084 (Pubitemid 30327261)
34. Svegliati-Baroni G, Saccomanno S, van Goor H, Jansen P, Benedetti A, Moshage H (2001) Involvement of reactive oxygen species and nitric oxide radicals in activation and proliferation of rat hepatic stellate cells. Liver 21(1):1-12 (Pubitemid 32112013)
35. Takahashi T, Ono H, Ono Y, Ishimitsu T, Matsuoka H (2007) Combination therapy with telmisartan and spironolactone alleviates L-NAME exacerbated nephrosclerosis with an increase in PPAR-gamma and decrease in TGF-beta(1). Int Heart J 48(5):637-647 (Pubitemid 350200186)
36. Tuncer I, Ozbek H, Ugras S, Bayram I (2003) Anti-fibrogenic effects of captopril and candesartan cilexetil on the hepatic fibrosis development in rat. The effect of AT1-R blocker on the hepatic fibrosis. Exp Toxicol Pathol 55(2-3):159-166 (Pubitemid 37309765)
37. Ueki M, Koda M, Yamamoto S, Matsunaga Y, Murawaki Y (2006) Preventive and therapeutic effects of angiotensin II type 1 receptor blocker on hepatic fibrosis induced by bile duct ligation in rats. J Gastroenterol 41(10):996-1004. doi: 10.1007/s00535-006-1891-1 (Pubitemid 44741413)
38. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352(9131):837-853 (Pubitemid 28416718)
39. Unal D, Aksak S, Halici Z, Sengul O, Polat B, Unal B, Halici M (2011) Effects of diabetes mellitus on the rat liver during the postmenopausal period. J Mol Histol 42(3):273-287. doi: 10.1007/s10735-011-9331-9
40. Uyanik A, Unal D, Uyanik MH, Halici Z, Odabasoglu F, Altunkaynak ZB, Cadirci E, Keles M, Gundogdu C, Suleyman H, Bayir Y, Albayrak M, Unal B (2010) The effects of polymicrobial sepsis with diabetes mellitus on kidney tissues in ovariectomized rats. Ren Fail 32(5):592-602. doi: 10.3109/08860221003759478
41. Wei HS, Li DG, Lu HM, Zhan YT, Wang ZR, Huang X, Zhang J, Cheng JL, Xu QF (2000) Effects of AT1 receptor antagonist, losartan, on rat hepatic fibrosis induced by CCl(4). World J Gastroenterol 6(4):540-545 (Pubitemid 30665265)
42. Wei YH, Jun L, Qiang CJ (2004) Effect of losartan, an angiotensin II antagonist, on hepatic fibrosis induced by CCl4 in rats. Dig Dis Sci 49(10):1589-1594 (Pubitemid 39335540)
43. Xu W, Song S, Huang Y, Gong Z (2006) Effects of perindopril and valsartan on expression of transforming growth factor-beta-Smads in experimental hepatic fibrosis in rats. J Gastroenterol Hepatol 21(8):1250-1256. doi: 10.1111/j.1440-1746.2006.04331.x (Pubitemid 44034336)
44. Yang S, Lin HZ, Hwang J, Chacko VP, Diehl AM (2001) Hepatic hyperplasia in noncirrhotic fatty livers: is obesity-related hepatic steatosis a premalignant condition? Cancer Res 61(13):5016-5023 (Pubitemid 32681529)
45. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, Tsujinoue H, Fukui H (2001) Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 34(4 Pt 1):745-750. doi: 10.1053/jhep.2001.28231 (Pubitemid 32927999)
46. Yoshiji H, Noguchi R, Ikenaka Y, Namisaki T, Kitade M, Kaji K, Shirai Y, Yoshii J, Yanase K, Yamazaki M, Tsujimoto T, Kawaratani H, Akahane T, Aihara Y, Fukui H (2009) Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat. BMC Res Notes 2:70. doi: 10.1186/1756-0500-2-70